There's an interesting poster that will be presented at the ASCO meeting about a combination regimen that includes pomalidomide [Pomalyst], the antibiotic clarithromycin (aka Biaxin), and dexamethasone. Here's a link to the abstract:
http://abstract.asco.org/AbstView_114_100048.html
The regimen is being tested in relapsed/refractory myeloma patients who have had at least 3 previous treatment regimens and have been treated with Revlimid.
Given the kind of patients that are in the study, especially that the patients all have been treated with Revlimid, which is chemically related to pomalidomide, the results struck me as very promising.
The overall response rate was 56 percent, but another 33 percent of the patients achieved either stable disease or a minimal response.
The study researchers summarize the results by saying the ClaPD regimen is "highly effective".
.
|
||
Independent, up-to-date news and information for the multiple myeloma community. |
|
